3D printing and nanotechnology have been two important tools in the development of therapeutic approaches for personalized medicine. More recently, their alliance has been improved in an effort to build innovative, versatile, multifunctional, and/or smart medical and pharmaceutical products. Therefore, an extensive review about scientific studies that ally 3D printing and nanomaterials in the development of new approaches for pharmaceutical and medical applications for the treatment and prevention of diseases is presented here. The articles are classified into five categories according to their main application: Cell growth and tissue engineering, antimicrobial, drug delivery, stimulus‐response, and theranostics. Semisolid extrusion, inorganic nanoparticles, and cell growth and tissue engineering are the most reported 3D printing technique, type of nanomaterial, and application, respectively. The increase in papers dedicated to these areas is also notable, especially in the 2019 and 2020, when semisolid extrusion became the most used technique, overcoming fused deposition modelling. In fact, this review highlights that the possibility of an alliance between 3D printing and nanotechnology for the production of multiscale materials is undoubtedly a great opportunity for knowledge and innovation in the pharmaceutical and medical area.

No abstract

No abstract

Emerging yeasts are among the most prevalent causes of systemic infections with high mortality rates and there is an urgent need to develop specific, effective and non-toxic antifungal agents to respond to this issue. In this study 35 aldehydes, hydrazones and hydrazines were obtained and their antifungal activity was evaluated against Candida species (C. parapsilosis, C. tropicalis, C. krusei, C. albicans, C. glabrata and C. lusitaneae) and Trichosporon asahii, in an in vitro screening. The minimum inhibitory concentrations (MICs) of the active compounds in the screening was determined against 10 clinical isolates of C. parapsilosis and 10 of T. asahii. The compounds 4-pyridin-2-ylbenzaldehyde] (13a) and tert-butyl-(2Z)-2-(3,4,5-trihydroxybenzylidine)hydrazine carboxylate (7b) showed the most promising MIC values in the range of 16-32 μg/mL and 8-16 μg/mL, respectively. The compounds' action on the stability of the cell membrane and cell wall was evaluated, which suggested the action of the compounds on the fungal cell membrane. Cell viability of OPEN ACCESSMolecules 2015, 20 9230 leukocytes and an alkaline comet assay were performed to evaluate the cytotoxicity. Compound 13a was not cytotoxic at the active concentrations. These results support the discovery of promising candidates for the development of new antifungal agents.

No abstract